Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP1) is a naturally occurring peptide secreted by intestinal L-cells. Though its primary function is to serve as an incretin, GLP1 reduces gastrointestinal motility. However, only a handful of animal studies have specifically evaluated the influence of GLP1 on colonic motility. Consequently, the aims of this study were to investigate the effects induced by exogenous GLP1, to analyze the mechanism of action, and to verify the presence of GLP1 receptors (GLP1Rs) in human colon circular muscular strips. Organ bath technique, RT-PCR, western blotting, and immunofluorescence were used. In human colon, exogenous GLP1 reduced, in a concentration-dependent manner, the amplitude of the spontaneous contractions without affecting the frequency and the resting basal tone. This inhibitory effect was significantly reduced by exendin (9–39), a GLP1R antagonist, which per se significantly increased the spontaneous mechanical activity. Moreover, it was abolished by tetrodotoxin, a neural blocker, or Nω-nitro-l-arginine – a blocker of neuronal nitric oxide synthase (nNOS). The biomolecular analysis revealed a genic and protein expression of the GLP1R in the human colon. The double-labeling experiments with anti-neurofilament or anti-nNOS showed, for the first time, that immunoreactivity for the GLP1R was expressed in nitrergic neurons of the myenteric plexus. In conclusion, the results of this study suggest that GLP1R is expressed in the human colon and, once activated by exogenous GLP1, mediates an inhibitory effect on large intestine motility through NO neural release.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“…the brain and http://joe.endocrinology-journals.org 2014 Society for Endocrinology DOI: 10.1530/JOE-13-0525 Printed in Great Britain pancreas (Baggio & Drucker 2007, Tornehave et al. 2008), hepatic cells (Gupta et al. 2010), adipocytes (Vendrell et al. 2011), and gastric mucosa (Broide et…”
BackgroundInfluentialGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“In fact, it inhibits gastric emptying, relaxes the antral region of the stomach, and reduces the motility of the upper intestine (Wettergren et al. 1993, Giralt & Vergara 1999, Miki et al. 2005, Nagell et al. 2006, Schirra et al. 2006, Amato et al. 2010, Rotondo et al. 2011).”
BackgroundGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · cited 2×
“…brain and http://joe.endocrinology-journals.org 2014 Society for Endocrinology DOI: 10.1530/JOE-13-0525 Printed in Great Britain pancreas (Baggio & Drucker 2007, Tornehave et al. 2008), hepatic cells (Gupta et al. 2010), adipocytes (Vendrell et al. 2011), and gastric mucosa (Broide et al. 2013).”
BackgroundMethodInfluentialGLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 2×
“Concerning the bowel, low levels of GLP1R protein expression have been found in duodenal Brunner’s glands and the myenteric plexus of the human gut, including the colon, by autoradiography (Körner et al. 2007), but the possible functions mediated by GLP1R in these regions remain purely hypothetic.”
BackgroundGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 2×
“In fact, previous studies have shown that the GLP1 receptor (GLP1R) is expressed in the CNS (Göke et al. 1995) and in the nodose ganglion (Nakagawa et al. 2004), and that exogenous GLP1 can activate vagal afferents (Bucinskaite et al. 2009).”
BackgroundRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450 · cited 1×
“Indeed, current knowledge of the GLP1R expression in human tissue is incomplete and based largely on receptor mRNA investigations in whole-organ preparations (Wei & Moisov 1995, Satoh et al. 2000).”
BackgroundGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432 · cited 3×
“…which GLP1 mediates inhibition of gastrointestinal motility has not been fully established, and likely involves the activation of vagal nerve (Imeryüz et al. 1997, Wettergren et al. 1998) and direct action on the gut wall from Bioscientifica.com at 11/22/2021 04:35:39PM via free access Jo u…”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · cited 1×
“Hep-G2 cell line (purchased from ATCC, Manassas, VA, USA) was used as positive control (Gupta et al. 2010, Svegliati-Baroni et al. 2011).”
MethodExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265 · cited 1×
“The inhibitory responses induced by GLP1 were significantly antagonized by exendin (9–39), a specific GLP1R antagonist (Schirra et al. 1998), indicating the specificity of the observed effect.”
BackgroundDelgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235 · cited 2×
“…mediators of the ileal brake (Giralt & Vergara 1999), slows gastric emptying, and reduces gastrointestinal motility (Imeryüz et al. 1997, Tolessa et al. 1998b, Näslund et al. 2001, 2002, Delgado-Aros et al. 2002, Miki et al. 2005, Shirra et al. 2006, Amato et al. 2010, Rotondo et al. 2011).”
BackgroundHamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227 · cited 1×
“The specificity of GLP1R antibody was previously demonstrated in mouse brain slides (Hamilton & Hölscher 2009) or in human retinal pigment epithelium cell line (Puddu et al. 2013).”
BackgroundVendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173 · cited 2×
“…brain and http://joe.endocrinology-journals.org 2014 Society for Endocrinology DOI: 10.1530/JOE-13-0525 Printed in Great Britain pancreas (Baggio & Drucker 2007, Tornehave et al. 2008), hepatic cells (Gupta et al. 2010), adipocytes (Vendrell et al. 2011), and gastric mucosa (Broide et al. 2013).”
BackgroundInfluentialTolessa, T., Gutniak, M., Holst, J. J., Efendic, S., & Hellström, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci942 · Cited by 139
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Amato, A., Cinci, L., Rotondo, A., Serio, R., Faussone-pellegrini, M. S., Vannucchi, M. G., & Mulè, F. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01476.x · Cited by 124 · cited 8×
“More recent evidence has suggested that the activation of enteric neurons mediates GLP1 inhibitory effects by nitric oxide (NO) release (Amato et al. 2010, Rotondo et al. 2011).”
BackgroundResultInfluentialSelf-citation
Cited by
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“(154) validated these findings by demonstrating that acute administration of GLP-1 activated the GLP-1R in human colon cells and resulted in an inhibitory effect on large intestine motility through release of neural NO.”
ResultRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-05323-7 · Cited by 160
Fukui, H., Xu, X., & Miwa, H. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18071 · Cited by 128
Effects of menthol on circular smooth muscle of human colon: Analysis of the mechanism of action
Amato, A., Liotta, R., & Mulè, F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.018 · Cited by 98
Self-citation
Metadata
- Authors
- Amato, A., Baldassano, S., Liotta, R., Serio, R., & Mulè, F.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2014-01-17
- Volume
- 221
- Issue
- 1
- Pages
- 29-37
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2001857679
- Cited by
- 48
- References
- 17
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.